NextFin

Elevance Health Raises 2026 Earnings Outlook to at Least $29 as Medical Costs Cool

Summarized by NextFin AI
  • Elevance Health raised full-year adjusted EPS guidance to at least $29.00 after Q3 medical costs came in cooler than expected, with GAAP diluted EPS of $6.27 beating the $4.71 consensus and adjusted EPS of $6.99.
  • The benefit expense ratio improved 70 basis points to 90.6%, translating to roughly $350 million of pre-tax benefit, driven by better Medicare Advantage and ACA plan performance, though days in claims payable rose 3.5 days to 44.9.
  • Medical membership fell 487,000 year over year to 44.9 million, concentrated in Medicaid, Medicare Advantage, and Employer Group risk businesses, raising concerns about fixed-cost leverage erosion despite premium yield discipline.
  • Shares rose 2.3% to $440.18, near a 52-week high, as investors priced in sector-wide cost relief, but the article warns the rally may be premature given membership erosion and a forward P/E of 16.15.

NextFin News - Elevance Health raised its full-year adjusted earnings guidance to at least $29.00 a share after third-quarter medical costs came in cooler than expected, a rare piece of good news for the managed-care industry at a time when peers are still wrestling with elevated benefit expenses. The company reported diluted earnings per share of $6.27 on a GAAP basis and $6.99 on an adjusted basis for the quarter ended September 30, with the GAAP print comfortably ahead of the $4.71 analysts had expected. It also lifted its operating cash-flow forecast to at least $6.5 billion. Shares rose 2.3% to $440.18 in New York on Wednesday, near a 52-week high of $440.67, as investors weighed the earnings beat against a continued loss of medical members.

The upgrade marks a sharp reversal from July, when the insurer's second-quarter results drew a muted response despite a guidance lift to at least $27.00 a share. This time, the market is treating the cost print as evidence that the medical-cost shock that battered Medicare Advantage margins over the past year is finally easing - and that Elevance may be the first large insurer to prove it.

The Numbers: A Beat Built on Lower Medical Costs

Elevance's third-quarter operating revenue rose 0.7% to $50.4 billion, a modest $0.4 billion increase over the prior-year quarter. The growth came from higher premium yields, increased CarelonRx product revenue, and service-fee growth, partly offset by lower Medicare Advantage, Medicaid, and Employer Group risk membership.

The margin story is where the quarter actually lives. The benefit expense ratio - the share of premium revenue consumed by medical claims - improved 70 basis points to 90.6% from 91.3% a year earlier, driven by better performance in Medicare Advantage and individual Affordable Care Act plans. A 70-basis-point swing across roughly $50 billion of quarterly revenue translates to about $350 million of pre-tax benefit that flowed straight to the bottom line.

On the bottom line, GAAP diluted EPS came in at $6.27, while adjusted diluted EPS reached $6.99. Management attributed part of the strength to a net non-operating benefit of $1.85 per share, which included favorable investment-related items. The adjusted operating expense ratio rose 90 basis points to 11.3%, reflecting targeted one-time investments in capabilities the company says will support long-term performance.

Guidance moved up across the board. Full-year adjusted diluted EPS guidance now stands at at least $29.00, up from at least $27.00. GAAP diluted EPS guidance rose to at least $22.00 from at least $20.10. Operating cash flow guidance increased to at least $6.5 billion from at least $6.0 billion. The company also reiterated confidence in delivering at least 12% adjusted diluted EPS growth in 2027, measured from a revised earnings baseline of at least $26.75.

"Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business," said Gail K. Boudreaux, President and Chief Executive Officer. "We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75."

Medical membership totaled approximately 44.9 million as of September 30, down 487,000 from a year earlier. The decline was concentrated in Medicaid, Medicare Advantage, and Employer Group risk-based businesses, partly offset by growth in commercial fee-based membership. The Health Benefits segment generated operating revenue of $43.4 billion, up 3% year over year. The Carelon services segment reported operating revenue of $19.3 billion, up 5%, with operating gain rising 17% to $0.9 billion.

The board declared a fourth-quarter dividend of $1.72 per share, payable December 18, 2026.

The Beat Was Real, but the Quality of Earnings Is Mixed

The headline beat is substantial: GAAP diluted EPS of $6.27 against a $4.71 consensus, and adjusted diluted EPS of $6.99 on management's preferred basis. But the composition of that beat matters, because not all of it came from underwriting.

The $1.85 per share net non-operating benefit - driven by favorable investment-related items - was a meaningful contributor to the quarter. Investment income is inherently less predictable than medical cost trends, and it can reverse quickly when interest rates move. A guidance raise anchored partly to non-operating income carries more execution risk than one built purely on underwriting discipline.

The margin bridge tells a similar story of mixed quality. While the benefit expense ratio improved 70 basis points, the adjusted operating expense ratio widened 90 basis points to 11.3%. The company says the increase reflects targeted one-time investments in member experience, provider connectivity, and operating efficiency. In other words, some of the medical-cost savings are being recycled into spending - which is sensible management, but it means the net margin benefit of the cost trend is smaller than the 70-basis-point benefit ratio improvement implies.

Operating margin edged down to 2.5% from 2.6% a year earlier, while adjusted operating margin held flat at 2.7%. For a company guiding to at least 12% earnings growth in 2027, that flat operating margin is the number to watch: growth will have to come from the earnings baseline stepping up, not from margin expansion this year.

Medical Cost Trend: Cyclical Relief or Structural Fix?

The central question for Elevance - and for the entire managed-care sector - is whether the 70-basis-point improvement in the benefit expense ratio is cyclical relief that will mean-revert, or a structural repair that will compound.

There is a credible case for cyclical relief. The improvement is measured against a prior-year quarter that was already stressed by elevated Medicare Advantage costs, so part of the swing is simply a favorable comparison. More tellingly, days in claims payable rose to 44.9 days as of September 30, up 3.5 days year over year. When an insurer holds claims longer before paying them, the current quarter's reported medical cost ratio improves - but those claims still have to be paid. If they are paid out in the fourth quarter, the benefit ratio improvement will partially reverse.

Days in claims payable is the single most important line item in this release, because it is the cleanest test of whether the cost improvement is real or a timing artifact. A 3.5-day build on a quarterly benefit expense base of roughly $38 billion represents about $1.4 billion of claims deferred into future quarters - more than the company's entire quarterly operating gain.

The structural case rests on two pillars. First, premium yield discipline: Elevance has been raising prices on commercial and ACA plans faster than medical trend for several quarters, and that pricing power shows up as a lower benefit ratio even if underlying utilization is unchanged. Second, Carelon: the services segment's 17% operating gain growth suggests the company is successfully shifting revenue toward fee-based businesses that do not carry insurance risk.

The verdict: the 70-basis-point improvement is mostly cyclical relief with a structural assist. The favorable prior-year comparison and the claims-payable build argue against treating it as a permanent margin reset. But the Carelon momentum and premium yield discipline are real structural positives that should persist regardless of the claims cycle. Investors should expect the benefit ratio to stabilize in the low-90s rather than continue improving at the current pace.

Membership Erosion Is the Bill That Hasn't Come Due

Beneath the cost beat lies a slower-moving problem: Elevance is losing members. Medical membership fell 487,000 year over year to 44.9 million, with declines in Medicaid, Medicare Advantage, and Employer Group risk businesses. Only commercial fee-based membership grew.

This matters because health insurance is a scale business. Fixed costs - provider network contracts, claims infrastructure, care management programs - are spread across the membership base. When membership shrinks while revenue grows only on price, the fixed-cost leverage that makes managed care profitable slowly erodes. Premium yield increases can offset membership losses for a while, but they cannot do so indefinitely without pricing the company out of competitive markets.

The Medicaid and Medicare Advantage exits are partly deliberate. Elevance has been pruning unprofitable Medicaid contracts and tightening Medicare Advantage underwriting after the cost shock of 2024-2025. That is rational capital allocation, and it explains why the company can lose members while improving margins. But it also means the membership decline is not purely a cyclical headwind that will bounce back - some of it is a structural repositioning that will weigh on premium revenue growth for several quarters.

Health Benefits revenue grew only 3% to $43.4 billion despite the premium yield increases, confirming that volume loss is already offsetting a meaningful portion of the price gains. If membership declines accelerate in 2027, the 12% earnings growth target becomes harder to reach even with a stable benefit ratio.

Peer context sharpens the point. UnitedHealth Group, Humana, Centene, and Molina are all navigating the same Medicaid redetermination cycle and Medicare Advantage cost pressures. Elevance's cost print is better than most, but the membership trend is a sector-wide issue, not an Elevance-specific one. The company's forward price-to-earnings ratio of 16.15 reflects a sector discount that will not fully close until membership stabilizes.

What the Market Priced In - and What It Hasn't

Before the release, the consensus full-year adjusted EPS estimate stood at $27.26 across 13 analysts, according to market data. The new guidance of at least $29.00 represents roughly $1.74 of upside to that consensus, or about 6%. That is a meaningful beat, but it is not a transformation.

The market reaction - a 2.3% gain to $440.18, near the 52-week high - suggests investors are pricing in more than the guidance raise itself. They are pricing in the inference that if Elevance's medical costs are under control, the worst of the managed-care margin cycle is over for the whole sector. That is the second-order trade, and it is where the risk lies.

The inference is plausible but premature. One company's favorable quarter, aided by a claims-payable build and a favorable prior-year comparison, does not establish a sector-wide inflection. UnitedHealth and Humana have not yet reported third-quarter results, and their medical cost trends could differ materially. Until the full sector reports, the "costs are under control" narrative rests on a single data point.

There is also an expectation gap embedded in the 2027 guidance. Management's confidence in at least 12% adjusted EPS growth next year, off a baseline of at least $26.75, implies earnings of roughly $30 or more in 2027. That assumes the benefit ratio holds near current levels while membership stabilizes and Carelon continues to grow at a double-digit pace. Any one of those assumptions failing would push 2027 earnings below the implied target.

The Counter-Thesis: This Is a Value Trap, Not a Turnaround

The strongest case against the bullish read is straightforward: Elevance is a value trap. The stock trades at a forward P/E of 16.15, well below its historical range, for a reason. The managed-care sector faces structural headwinds - government reimbursement pressure on Medicare Advantage, Medicaid enrollment normalization after the pandemic-era expansion, and political scrutiny of insurer margins - that a single good cost quarter does not erase.

Under this view, the 70-basis-point benefit ratio improvement is a cyclical bounce that will reverse as the claims payable build unwinds and as medical utilization continues to rise with an aging membership base. The membership losses, meanwhile, are structural and will cap revenue growth regardless of pricing discipline. The result is a company that looks cheap on trailing earnings but keeps compounding at a low single-digit rate - the classic definition of a value trap.

This thesis has institutional support. Analysts at major investment banks have repeatedly cut managed-care price targets over the past year on exactly these grounds: that medical cost inflation is sticky, that government programs pay less than commercial business, and that membership churn in Medicaid is a multi-year headwind. The sector's underperformance relative to the broader market over the past three years - Elevance is up only 1.24% over three years versus 82.58% for the S&P 500 - is the market's verdict on the value-trap argument.

The counter-thesis is answered, but not eliminated, by two facts. First, Elevance's benefit ratio improvement was driven by Medicare Advantage and ACA - the two segments where the cost shock was most severe - suggesting the worst really may be behind the company in its most exposed lines. Second, Carelon's 17% operating gain growth shows the company is building a fee-based earnings stream that is insulated from medical cost trends. These are real structural positives, but they are not yet large enough to fully offset the insurance book's headwinds.

The falsifying signal is specific: if Elevance's fourth-quarter 2026 benefit expense ratio comes back above 91.3% - the level of the prior-year quarter - while medical membership continues to decline, the "costs are under control" thesis is wrong. That combination would confirm that the third-quarter improvement was a timing artifact and that membership erosion is now the dominant driver of earnings.

What to Watch Next

Three data points will determine whether this rally has legs. First, days in claims payable in the fourth quarter: if it normalizes back toward the low-40s, expect a corresponding benefit ratio reversal. Second, medical membership trends in the fourth quarter and in 2027 guidance detail: stabilization is the minimum requirement for the bull case. Third, peer results from UnitedHealth and Humana: confirmation of sector-wide cost relief would validate the second-order trade; divergence would isolate Elevance as a single-name story.

Scenarios for the next 12 months:

  • Base case: Elevance delivers at least $29.00 adjusted EPS in 2026, membership declines moderate, and the benefit ratio stabilizes in the low-90s. The stock rerates toward a 17-18x forward P/E as the sector discount narrows.
  • Upside case: The claims payable build proves to be modest, the benefit ratio holds below 91%, and Carelon accelerates toward double-digit operating gain growth. Earnings approach the $30-plus level implied by 2027 guidance a year early, and the stock tests new highs above $440.
  • Downside case: The fourth-quarter benefit ratio reverses above 91.3%, membership losses accelerate, and peers report weaker cost trends. The guidance raise is recharacterized as premature, and the stock falls back toward its 50-day moving average near $405.

The time-horizon split is clear. In the short term, the rally is justified: the earnings beat is real, the guidance raise is credible, and the stock was cheap. Over the medium term, everything depends on membership stabilization and the durability of the cost trend - neither of which is confirmed yet. Over the long term, the investment case rests on whether Carelon can transform Elevance from a pure insurer into a diversified health services company; that transformation is underway but far from complete.

Elevance's cost relief is real, but the market is paying for a turnaround that membership trends have not yet confirmed.

Market data as of Wednesday's session; company figures from the third-quarter 2026 earnings release.

Explore more exclusive insights at nextfin.ai.

Insights

Why raise Elevance 2026 earnings?

How cool are medical costs now?

What is Elevance Q3 adjusted EPS?

Did membership losses hurt growth?

Is the benefit ratio fix structural?

How do claims payable days impact?

What drives Carelon segment growth?

Is Elevance stock a value trap?

How do peers compare medical costs?

Will 2027 growth target hold true?

What risks face managed care sector?

Why did shares rise after report?

How does pricing power help margins?

Is membership erosion truly reversible?

What defines adjusted operating margin?

Can Carelon offset insurance risks?

What signals confirm cost control?

How does Medicaid status affect revenue?

Will sector discount narrow soon?

What defines the downside case scenario?

Search, ask or analyze anything...